Table 2.
Features entered the LASSO for PFS in the training cohort.
| Variables | Coefficients (λ.min) | Coefficients (λ.1se) |
|---|---|---|
| Age (y) | – | – |
| Sex (male/female) | – | – |
| Cause of HCC (hepatitis B/other) | – | – |
| ALT (U/L) | – | – |
| AST (U/L) | 0.006412359 | 0.003018912 |
| NLR | 0.042218270 | – |
| PLR | – | – |
| PLT (×109/L) | – | – |
| ALB (g/L) | – | – |
| TBIL (μmol/L) | – | – |
| Child-Pugh class (A/B) | – | – |
| AFP (ng/mL) (≤400/>400) | – | – |
| No. of lesions (solitary/multifocal) | 0.099686063 | – |
| Diameter (cm) | 0.063100231 | 0.046008561 |
| Vascular invasion (absent/present) | – | – |
| Tumor extent (unilobar/bilobar) | – | – |
| Enhancing capsule (absent/present) | – | – |
| Margin appearance (smooth/non-smooth) | 0.177587833 | – |
| AEF of residual tumor (%) | 0.014771557 | 0.004969961 |
The “–” means zero coefficient of the variable at respective λ value. AEF-RT, arterial enhancement fraction of residual tumor; AFP, α-fetoprotein; ALT, alanine transaminase; AST, aspartate transaminase; HR, hazard ratio; LASSO, least absolute shrinkage and selection operator; NLR, neutrophil-to-lymphocyte ratio; PFS, progression-free survival; PLR, platelet−to−lymphocyte ratio; PLT, peripheric platelet count; TBIL, total bilirubin.